Highest-materiality recent filing
Viemed Healthcare shareholders approve LTIP amendment, increase share reserve to 7.70M
LTIP share reserve increased to 7,696,717 shares, including up to 1M incentive stock options.
Viemed Healthcare files investor presentation with no material updates
Filed investor deck under Item 7.01 Regulation FD; no earnings or guidance provided.
Viemed Healthcare reports Q1 2026 revenue of $75.4M, raises full-year guidance
Net revenues increased 28% to $75.4 million for Q1 2026, up from $59.1 million in Q1 2025.
Viemed files March 2026 investor deck with no material new data disclosed
Investor deck titled 'A Rapidly Growing National Leader In Home-Based Clinical Care' filed as Exhibit 99.1.
Viemed posts record FY2025 revenue $270.3M; net income +33%; guides FY2026 rev $310-320M
Q4 revenue $76.2M (record, +26% YoY); FY revenue $270.3M (record, +21% YoY).
Viemed extends delayed draw term loan commitment to Nov 2026 and furnishes investor presentation
Amendment extends delayed draw term loan commitment expiration from Nov 29, 2025 to Nov 29, 2026.
Viemed Q3 revenue record $71.9M, up 24% YoY; guides FY rev $271-273M
Net revenues $71.9M, a company record, up 24% YoY from $58.0M.
Viemed completes $13.2M share buyback of 1.98M shares (5% of outstanding)
Repurchased 1,976,441 common shares for approximately $13.2M at weighted average price of $6.69 per share.
Viemed Q2 net revenue $63.1M (record, +14.7% YoY); diluted EPS $0.08 vs $0.04
Net revenues for Q2 2025 hit $63.1M, a record high, up 14.7% from $55.0M in Q2 2024.
Viemed closes acquisition of Lehan's Medical Equipment for $26M base plus $2.2M earnout
Base purchase price $26M (subject to adjustments) plus estimated contingent consideration of ~$2.2M.
Viemed authorizes share repurchase of up to 1.98M shares (~5% of outstanding) through June 2026
Board authorized repurchase of up to 1,976,441 common shares (approx. 5% of outstanding) through June 2026.
Shareholders approve amendment to 2024 LTIP, increasing share pool to ~7.9M
Amendment increases maximum shares available under 2024 LTIP to 7,904,769.
Viemed reports Q1 2025 revenue of $59.1M, up 17% YoY; net income rises 64%
Q1 net revenues $59.1M, 17% increase from $50.6M in Q1 2024.
Viemed acquires Lehan's Medical Equipment for $26M base price; diversifies into women's health
Base purchase price $26M, plus ~$2.2M contingent payments; expected close Q3 2025.
Bruce Greenstein resigns from Viemed Healthcare board effective April 14, 2025
Resignation was effective immediately; no replacement has been announced.
Viemed posts March 2025 investor presentation; no specific financial updates in filing
Company furnished an investor deck covering home respiratory care leadership and business overview.
Viemed posts record Q4 revenue $60.7M; full year net revenue $224.3M; issues 2025 guidance
Q4 net revenue $60.7M (+20% YoY); full year $224.3M (+23% YoY).
Viemed files investor presentation; no specific financial details provided in filing
Furnished an investor presentation (Exhibit 99.1) under Item 7.01.
Viemed Healthcare Q3 2024: revenue up 17.4% to $58M, net income up 33%
Net revenues of $58.0M, a company record; up 17.4% YoY and 5.5% sequentially.
Viemed furnishes August 2024 investor deck; no material new disclosures
Presentation provides general business overview and strategy for home respiratory care.
Viemed Q2 2024 revenue hits record $55.0M, up 27% YoY; Adjusted EBITDA up 31%
Net revenues $55.0M (record), up 27% YoY and 9% sequential from Q1 2024.
Viemed shareholders approve 2M-share 2024 LTIP; directors elected with notable withhold votes
Shareholders approved 2024 Long Term Incentive Plan authorizing up to 2,000,000 common shares for equity awards.
Viemed Healthcare extends delayed draw term loan commitment to Nov 2025
Extended delayed draw term loan commitment expiration from May 29, 2024 to November 29, 2025.
Viemed furnishes May 2024 investor deck; no specific new financial data provided in exhibit
Filing is a Regulation FD disclosure of an investor presentation used for meetings.
Viemed Q1 2024 revenue $50.6M, up 28% YoY; net income $1.6M
Net revenues $50.6M for Q1 2024, increase of $11.0M or 28% vs Q1 2023.
Viemed acquires majority stake in East Alabama HomeMed; expects ~$4M annual revenue
Transaction closed April 1, 2024; Viemed gains controlling interest and managerial control of HomeMed.
Viemed files March 2024 investor deck with no specific new financial targets disclosed
Company posted slide deck to investors covering home respiratory care market position.
Viemed reports record Q4 revenue $50.7M (+35% YoY); net income up 43%
Q4 2023 revenue $50.7M, up 35% from $37.5M in Q4 2022; full-year revenue $183.0M, up 32%.
On April 14, 2025, Bruce Greenstein notified Viemed Healthcare, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors, effective immediately.
Max materiality 0.75 · Median 0.57 · Most common event earnings